Unknown

Dataset Information

0

Crystallographic insights into the structure-activity relationships of diazaborine enoyl-ACP reductase inhibitors.


ABSTRACT: Enoyl-ACP reductase, the last enzyme of the fatty-acid biosynthetic pathway, is the molecular target for several successful antibiotics such as the tuberculosis therapeutic isoniazid. It is currently under investigation as a narrow-spectrum antibiotic target for the treatment of several types of bacterial infections. The diazaborine family is a group of boron heterocycle-based synthetic antibacterial inhibitors known to target enoyl-ACP reductase. Development of this class of molecules has thus far focused solely on the sulfonyl-containing versions. Here, the requirement for the sulfonyl group in the diazaborine scaffold was investigated by examining several recently characterized enoyl-ACP reductase inhibitors that lack the sulfonyl group and exhibit additional variability in substitutions, size and flexibility. Biochemical studies are reported showing the inhibition of Escherichia coli enoyl-ACP reductase by four diazaborines, and the crystal structures of two of the inhibitors bound to E. coli enoyl-ACP reductase solved to 2.07 and 2.11 Å resolution are reported. The results show that the sulfonyl group can be replaced with an amide or thioamide without disruption of the mode of inhibition of the molecule.

SUBMITTER: Jordan CA 

PROVIDER: S-EPMC4666481 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Crystallographic insights into the structure-activity relationships of diazaborine enoyl-ACP reductase inhibitors.

Jordan Cheryl A CA   Sandoval Braddock A BA   Serobyan Mkrtich V MV   Gilling Damian H DH   Groziak Michael P MP   Xu H Howard HH   Vey Jessica L JL  

Acta crystallographica. Section F, Structural biology communications 20151127 Pt 12


Enoyl-ACP reductase, the last enzyme of the fatty-acid biosynthetic pathway, is the molecular target for several successful antibiotics such as the tuberculosis therapeutic isoniazid. It is currently under investigation as a narrow-spectrum antibiotic target for the treatment of several types of bacterial infections. The diazaborine family is a group of boron heterocycle-based synthetic antibacterial inhibitors known to target enoyl-ACP reductase. Development of this class of molecules has thus  ...[more]

Similar Datasets

| S-EPMC5676022 | biostudies-literature
| S-EPMC4278936 | biostudies-literature
| S-EPMC10694131 | biostudies-literature
| S-EPMC3361726 | biostudies-literature
| S-EPMC2330183 | biostudies-literature
| S-EPMC2693028 | biostudies-literature
| S-EPMC3397485 | biostudies-literature
| S-EPMC5947681 | biostudies-literature
| S-EPMC2526048 | biostudies-literature
| S-EPMC4887296 | biostudies-literature